News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
848,275 Results
Type
Article (77051)
Company Profile (336)
Press Release (770868)
Multimedia
Podcasts (257)
Webinars (39)
Section
Business (258507)
Career Advice (3843)
Deals (38804)
Drug Delivery (191)
Drug Development (88725)
Employer Resources (208)
FDA (18442)
Job Trends (17070)
News (385431)
Policy (38610)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (4)
2027 Genetown Standard (7)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (7)
Academia (3073)
Academic (2)
Accelerated approval (65)
ADA (50)
Adcomms (44)
Allergies (217)
Alliances (55800)
ALS (252)
Alzheimer's disease (2064)
Antibody-drug conjugate (ADC) (624)
Approvals (18882)
Artificial intelligence (926)
ASCO (344)
Autoimmune disease (405)
Automation (71)
Bankruptcy (390)
Best Places to Work (12623)
BIO (80)
Biologics (1)
BIOSECURE Act (23)
Biosimilars (274)
BioSpace Insights (243)
Biotechnology (238)
Bladder cancer (225)
Brain cancer (86)
Breast cancer (886)
Cancer (7037)
Cardiovascular disease (601)
Career advice (3312)
Career pathing (58)
CAR-T (408)
CDC (77)
Celiac Disease (3)
Cell therapy (1119)
Cervical cancer (60)
Clinical research (77234)
Collaboration (2584)
Commercialization (9)
Company closure (9)
Compensation (1701)
Complete response letters (122)
COVID-19 (3052)
CRISPR (133)
C-suite (1464)
Cystic fibrosis (173)
Data (9348)
Decentralized trials (3)
Denatured (99)
Depression (211)
Dermatology (119)
Diabetes (740)
Diagnostics (7736)
Digital health (76)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (469)
Drug pricing (247)
Drug shortages (39)
Duchenne muscular dystrophy (355)
Earnings (99374)
Editorial (82)
Employer branding (25)
Employer resources (178)
Events (135493)
Executive appointments (1288)
FDA (22913)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (25)
Frontotemporal dementia (38)
Funding (2103)
Gene editing (291)
Generative AI (90)
Gene therapy (888)
GLP-1 (1323)
Government (5538)
Grass and pollen (8)
Guidances (434)
Healthcare (21265)
Hematology (197)
HIV (108)
Huntington's disease (74)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (129)
Immunology and inflammation (382)
Immuno-oncology (126)
Indications (241)
Infectious disease (3471)
Inflammatory bowel disease (249)
Inflation Reduction Act (17)
Influenza (156)
Intellectual property (350)
Interviews (747)
IPO (17785)
IRA (61)
Job creations (4766)
Job search strategy (2655)
JPM (73)
Kidney cancer (27)
Labor market (131)
Layoffs (703)
Leadership (58)
Legal (9646)
Licensing (12)
Liver cancer (112)
Longevity (39)
Lung cancer (941)
Lymphoma (510)
Machine learning (69)
Management (69)
Manufacturing (1369)
Marketing (14)
MASH (235)
Medical affairs (1)
Medical device (15320)
Medtech (15560)
Mergers & acquisitions (22458)
Metabolic disorders (1921)
mRNA (289)
Multiple sclerosis (218)
NASH (24)
Neurodegenerative disease (562)
Neuropsychiatric disorders (139)
Neuroscience (3970)
Neurotech (1)
NextGen: Class of 2026 (7596)
Non-profit (5154)
Now hiring (89)
Obesity (912)
Opinion (388)
Ovarian cancer (259)
Pain (303)
Pancreatic cancer (387)
Parkinson's disease (445)
Partnered (43)
Patents (723)
Patient recruitment (902)
Peanut (73)
People (66935)
Pharmaceutical (68)
Pharmacy benefit managers (38)
Phase 1 (23961)
Phase 2 (33636)
Phase 3 (25445)
Pipeline (11594)
Policy (412)
Postmarket research (3156)
Preclinical (10494)
Press Release (72)
Prostate cancer (371)
Psychedelics (87)
Radiopharmaceuticals (396)
Rare diseases (1417)
Real estate (7100)
Recruiting (83)
Regulatory (30191)
Reports (85)
Research institute (2784)
Resumes & cover letters (609)
Rett syndrome (50)
RNA editing (32)
RSV (102)
Schizophrenia (205)
Series A (363)
Series B (266)
Service/supplier (15)
Sickle cell disease (136)
Special edition (34)
Spinal muscular atrophy (192)
Sponsored (56)
Startups (4191)
State (2)
Stomach cancer (21)
Supply chain (154)
Tariffs (105)
The Weekly (155)
Vaccines (1356)
Venture capital (152)
Weight loss (617)
Women's health (157)
Worklife (25)
Date
Today (103)
Last 7 days (527)
Last 30 days (2725)
Last 365 days (32916)
2026 (21338)
2025 (32417)
2024 (37482)
2023 (42549)
2022 (53910)
2021 (58694)
2020 (57638)
2019 (51287)
2018 (39073)
2017 (36722)
2016 (37394)
2015 (44111)
2014 (39283)
2013 (35119)
2012 (35490)
2011 (35440)
2010 (33769)
Location
Africa (1201)
Alabama (108)
Alaska (7)
Arizona (422)
Arkansas (16)
Asia (50385)
Australia (8616)
California (15369)
Canada (4264)
China (1754)
Colorado (661)
Connecticut (682)
Delaware (474)
Europe (115062)
Florida (2335)
Georgia (503)
Hawaii (5)
Idaho (70)
Illinois (1318)
India (126)
Indiana (702)
Iowa (28)
Japan (661)
Kansas (151)
Kentucky (60)
Louisiana (66)
Maine (95)
Maryland (1844)
Massachusetts (11150)
Michigan (431)
Minnesota (854)
Mississippi (7)
Missouri (177)
Montana (37)
Nebraska (31)
Nevada (164)
New Hampshire (92)
New Jersey (4046)
New Mexico (38)
New York (4038)
North Carolina (2027)
North Dakota (11)
Northern California (7761)
Ohio (482)
Oklahoma (31)
Oregon (48)
Pennsylvania (2974)
Puerto Rico (33)
Rhode Island (55)
South America (1585)
South Carolina (93)
South Dakota (2)
Southern California (6101)
Tennessee (255)
Texas (2513)
United States (54699)
Utah (467)
Vermont (2)
Virginia (388)
Washington D.C. (88)
Washington State (1241)
West Virginia (4)
Wisconsin (174)
Wyoming (3)
848,275 Results for "merck sharp and dohme".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.
August 4, 2026
·
3 min read
·
Gabrielle Masson
Press Releases
Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update
July 15, 2026
·
4 min read
Press Releases
Sharp Therapeutics Announces Closing of Non-Brokered Private Placement
July 29, 2026
·
4 min read
Approvals
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
July 16, 2026
·
2 min read
·
Gabrielle Masson
Cancer
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.
August 19, 2026
·
3 min read
·
Nick Paul Taylor
Press Releases
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
July 21, 2026
·
3 min read
Press Releases
Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date
Shareholders Must Recast Their Votes to be Counted
June 30, 2026
·
4 min read
HIV
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble
While Merck and Gilead Sciences reported back-to-back late-stage victories for their weekly HIV pill, the partners also discontinued a Phase 3 program for their cancer combo after disappointing lung cancer survival data.
June 9, 2026
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms
Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.
June 23, 2026
·
2 min read
·
Tristan Manalac
Cancer
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer
Merck and Kelun-Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to file for approval.
May 19, 2026
·
2 min read
·
Tristan Manalac
1 of 84,828
Next